The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells

Ran Xu; Yuqiang Mao; Kuanbing Chen; Wei He; Wenjun Shi; Yun Han

doi:10.18632/oncotarget.16640

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells

Ran Xu _, Yuqiang Mao, Kuanbing Chen, Wei He, Wenjun Shi and Yun Han

PDF | HTML | How to cite

Oncotarget. 2017; 8:39177-39184. https://doi.org/10.18632/oncotarget.16640

Metrics: PDF 1827 views | HTML 2220 views | ?

Abstract

Ran Xu1, Yuqiang Mao1, Kuanbing Chen1, Wei He1, Wenjun Shi1 and Yun Han1

1Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

Correspondence to:

Yun Han, email: [email protected]

Keywords: long noncoding RNA, ANRIL, lung adenocarcinoma, chemotherapy resistance, paclitaxel

Received: February 07, 2017 Accepted: March 04, 2017 Published: March 29, 2017

ABSTRACT

Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that might affect Lung adenocarcinoma (LAD) chemo-resistance and most of them could be used as biomarkers and therapy targets. However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown. This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism. Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. These findings might improve LAD patients’ paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16640

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells

Abstract